DR-163 Molecular archaeology of cancer metastases

No Featured Image set

We aim to apply computational tools to Hartwig Medical Foundation cancer genomes to establish the order in which harmful mutations were acquired, and approximately when they were acquired during a patient’s lifetime. Furthermore, we aim to infer what caused the mutations (for example, smoking, UV light, etc.), and estimate when the cell was exposed to these damaging processes. Across many cancer samples, this approach lets us build a picture of how different cancers evolve over time. By comparing these results to earlier analyses we performed on primary tumours (observed at initial cancer diagnosis), we seek to understand the development of cancer as it spreads from the initial site to another site (known as metastasis). This will show whether tumours that metastasise evolve in the same way as non-metastatic cancers, and may give insight that helps to predict the metastatic step in cancer evolution.

Peter van Loo The Francis Crick Institute United Kingdom

Terug naar nieuws

Meer nieuws

Wat doet Hartwig Medical Foundation met alle verzamelde data?

Wat doet Hartwig Medical Foundation met alle verzamelde data?

12-10-2016

Regelmatig krijgen wij bij Hartwig Medical Foundation vragen rondom de onderwerpen eigendom van data, publicatierecht en intellectual property (IP). Om …

Certificaat databeveiliging vernieuwd

Certificaat databeveiliging vernieuwd

16-04-2024

“Binnen alle pijlers in control” zei de beoordelaar bij de controle van onze databeveiliging. In vier dagen is de hele organisatie …

Whole Genome Sequencing voor kankerdiagnostiek klinisch gevalideerd

Whole Genome Sequencing voor kankerdiagnostiek klinisch gevalideerd

18-05-2021

Wetenschappelijk onderzoek heeft aangetoond dat Whole Genome Sequencing (WGS) minstens gelijkwaardig is aan routinediagnostiek. Klinisch Moleculair Bioloog in de Pathologie …

Wilt u op de hoogte blijven van nieuwe ontwikkelingen?

Abonneer u op onze nieuwsbrieven

Meer weten over de complete DNA-test?

Ga naar OncoAct.nl